EP3316881A4 - System and method for diagnosis and treatment - Google Patents

System and method for diagnosis and treatment Download PDF

Info

Publication number
EP3316881A4
EP3316881A4 EP16898785.7A EP16898785A EP3316881A4 EP 3316881 A4 EP3316881 A4 EP 3316881A4 EP 16898785 A EP16898785 A EP 16898785A EP 3316881 A4 EP3316881 A4 EP 3316881A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16898785.7A
Other languages
German (de)
French (fr)
Other versions
EP3316881A1 (en
Inventor
Randice Lisa Altschul
Neil David THEISE
Myron Rapkin
Rebecca O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pop Test Oncology LLC
Original Assignee
Pop Test Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/802,060 external-priority patent/US9314473B2/en
Application filed by Pop Test Oncology LLC filed Critical Pop Test Oncology LLC
Priority claimed from PCT/US2016/026876 external-priority patent/WO2017180086A1/en
Publication of EP3316881A1 publication Critical patent/EP3316881A1/en
Publication of EP3316881A4 publication Critical patent/EP3316881A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16898785.7A 2015-07-17 2016-04-11 System and method for diagnosis and treatment Pending EP3316881A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/802,060 US9314473B2 (en) 2011-02-03 2015-07-17 System and method for diagnosis and treatment
PCT/US2016/026876 WO2017180086A1 (en) 2016-04-11 2016-04-11 System and method for diagnosis and treatment

Publications (2)

Publication Number Publication Date
EP3316881A1 EP3316881A1 (en) 2018-05-09
EP3316881A4 true EP3316881A4 (en) 2019-05-29

Family

ID=61767978

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16898785.7A Pending EP3316881A4 (en) 2015-07-17 2016-04-11 System and method for diagnosis and treatment

Country Status (1)

Country Link
EP (1) EP3316881A4 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RATHKOPF DANA E ET AL: "Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 31, no. 28, 1 October 2013 (2013-10-01), pages 3525 - 3530, XP008166079, ISSN: 0732-183X, [retrieved on 20130903], DOI: 10.1200/JCO.2013.50.1684 *
See also references of WO2017180086A1 *

Also Published As

Publication number Publication date
EP3316881A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
EP3264980A4 (en) System and method for patient positioning
EP3179918A4 (en) Treatment procedure planning system and method
EP3001196B8 (en) Blood testing system and method
EP3232941A4 (en) Surgical method and system for performing the same
IL254596A0 (en) Method for operating reverse-osmosis-membrane treatment system and reverse-osmosis-membrane treatment system
EP3357402A4 (en) Endoscope system and operation method for endoscope system
EP3174600A4 (en) System and method for optogenetic therapy
EP3111819A4 (en) Medical system and treatment tool calibration method
EP3103411A4 (en) Surgical system and method for operating surgical system
EP3326566A4 (en) Medical system and operation method therefor
EP3260423A4 (en) Water treatment system and method
GB201600873D0 (en) System and method for endoscope callibration
EP3107642A4 (en) Systems and methods for treating blood
EP3087941A4 (en) Therapeutic treatment system, and operating method for therapeutic treatment system
EP3299918A4 (en) Abnormality diagnosis system and abnormality diagnosis method
EP3117231A4 (en) System and method for low-field, multi-channel imaging
EP3229093A4 (en) Abnormality diagnosis method and abnormality diagnosis system
EP3286142A4 (en) Liquid treatment system and method
EP3395227A4 (en) Endoscope system and operation method for endoscope system
EP3383473A4 (en) Blood testing system and method
EP3127469A4 (en) Endoscope system and operation method thereof
EP3117770A4 (en) Medical imaging system and operation method therefor
EP3326139A4 (en) Patient coordination system and method
EP3360459A4 (en) Endoscope system and operation method for endoscope system
HK1211355A1 (en) Medical assistance method and system

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20190124BHEP

Ipc: A61K 31/357 20060101AFI20190124BHEP

Ipc: A61K 45/06 20060101ALI20190124BHEP

Ipc: A61K 31/395 20060101ALI20190124BHEP

Ipc: A61P 35/00 20060101ALI20190124BHEP

Ipc: A61K 31/4439 20060101ALI20190124BHEP

Ipc: A61K 31/575 20060101ALI20190124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190430

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/395 20060101ALI20190424BHEP

Ipc: A61K 31/575 20060101ALI20190424BHEP

Ipc: A61K 45/06 20060101ALI20190424BHEP

Ipc: A61K 31/4439 20060101ALI20190424BHEP

Ipc: A61P 35/00 20060101ALI20190424BHEP

Ipc: A61P 31/00 20060101ALI20190424BHEP

Ipc: A61K 31/357 20060101AFI20190424BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS